Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
URMC / Research / Clinical Trials / Study Details

IGIP19008 / ERYTECH Pharma / Aram Hezel

Research Question:
Does the the addition of eryaspase to chemotherapy improve patient health compared to chemotherapy alone?

Basic Study Information

This is an open-label, multicenter, randomized, Phase 3 study in patients with ductal adenocarcinoma of the pancreas who have failed only one prior line of systemic anti-cancer therapy for advanced pancreatic cancer and have measurable disease.

Location: University of Rochester Medical Center
Study Reference #: IGIP19008

Lead Researcher (Principal Investigator)

Lead Researcher:  Aram Hezel

Study Contact Information

Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475

Additional Study Details

Return to Search